Driven by our passion for patients and grounded in our industry-leading pipeline of 45+ different compounds across 70+ development programs, Novartis is rapidly advancing novel cancer treatment approaches in areas of great medical need. Current meeting ASCO Annual Meeting 2023 - June 2-6, 2023 At ASCO this year, we will share new data from our robust portfolio and pipeline of advanced therapeutic platforms in cancer and blood disorders, showcasing the impact of our bold science in research. Previous years archive ASCO Annual Meeting 2022 Learn more on what happened at ASCO 2022 ASCO Annual Meeting 2021 Learn more on what happened at ASCO 2021 ASCO Annual Meeting 2020 Learn more on what happened at ASCO 2020 Latest ASCO related media releases Apr 26, 2023 Media Release Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO Jun 03, 2022 Media Update New CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with consistently proven overall survival benefit in HR+/HER2- metastatic breast cancer May 12, 2022 Media Release Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer View more